Virax Biolabs Group Limited
VRAX · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $3,531 | $1,475 | $7,392 | $207,008 |
| - Cash | $4,229 | $3,589 | $9,353 | $22 |
| + Debt | $377 | $224 | $146 | $4 |
| Enterprise Value | -$321 | -$1,890 | -$1,814 | $206,990 |
| Revenue | $6 | $156 | $9 | $0 |
| % Growth | -96% | 1,727.1% | – | – |
| Gross Profit | -$53 | $51 | -$1 | $0 |
| % Margin | -838.2% | 32.3% | -15.9% | – |
| EBITDA | -$5,802 | -$6,609 | -$5,442 | -$1 |
| % Margin | -91,649.5% | -4,225.3% | -63,570.7% | – |
| Net Income | -$6,061 | -$6,734 | -$5,457 | -$1,709 |
| % Margin | -95,739.2% | -4,304.8% | -63,748.3% | – |
| EPS Diluted | -1.95 | -3.36 | -5.13 | -1.5 |
| % Growth | 42% | 34.5% | -242% | – |
| Operating Cash Flow | -$4,564 | -$6,247 | -$4,180 | -$809 |
| Capital Expenditures | -$604 | -$1,164 | -$178 | $0 |
| Free Cash Flow | -$5,167 | -$7,411 | -$4,358 | -$809 |